scPharmaceuticals

Accelerated At-Home Care Will Drive FUROSCIX And sc2Wear Adoption

AnalystHighTarget

Not Invested

Consensus Narrative from 3 Analysts

Published

31 Aug 25

AnalystHighTarget's Fair Value

US$25.00

77.7% undervalued

05 Sep

US$5.57

9.0%

1.3%

9.0%

1.3%

Edit anytime before Aug 31 9:47 PM. Then post Updates to your followers.

Author's Valuation

US$25.0

77.7% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$25.0

77.7% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

33.99%

Pharma revenue growth rate

0.59%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$117.56m

Earnings '28

16.57x

PE Ratio '28

US$1.95b

Market Cap '28

US$1.95b

Market Cap '28

64.40m

No. shares '28

US$30.24

Share Price '28

US$30.24 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$24.84

Fair Value '25